Literature DB >> 17098487

Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.

Stephen R Edwards1, Maree T Smith.   

Abstract

A method was developed for quantification of oxycodone, noroxycodone, and oxymorphone in small volumes (50 microl) of rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry using turbo ion-spray. Deuterated (d3) opioid analogues acted as internal standards. Sample preparation involved protein precipitation with acetonitrile, centrifugal evaporation, and reconstitution in mobile phase; analyte separation was performed on a C18 (5 microm, 2.1 mm x 50 mm) column using a linear gradient program. Lower limits of quantitation (ng/ml) and their between-day accuracy and precision were-oxycodone, 0.9 (-0.2 and 7.8%); noroxycodone, 1.0 (0.6 and 6.2%); oxymorphone 1.0 (-1.8 and 9.5%).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098487     DOI: 10.1016/j.jchromb.2006.10.039

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Authors:  Janet Hardy; Ross Norris; Helen Anderson; Angela O'Shea; Bruce Charles
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

2.  Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.

Authors:  Kristin Moksnes; Stein Kaasa; Ørnulf Paulsen; Jan Henrik Rosland; Olav Spigset; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2012-02-29       Impact factor: 2.953

3.  Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?

Authors:  Bruce Charles; Janet Hardy; Helen Anderson; Angela Tapuni; Rani George; Ross Norris
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

4.  Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.

Authors:  Wenfang B Fang; Michelle R Lofwall; Sharon L Walsh; David E Moody
Journal:  J Anal Toxicol       Date:  2013-06-05       Impact factor: 3.367

5.  Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

Authors:  Trine Naalsund Andreassen; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2010-12-08       Impact factor: 2.953

6.  A high-throughput bioanalytical assay to support pharmacokinetic interaction study of oxycodone and diazepam in Sprague Dawley rats.

Authors:  Nageswara R Pilli; Suresh Narayanasamy; Lin Xu; Ashok Chockalingam; Katherine I Shea; Sharron Stewart; Rodney Rouse; Vikram Patel; Murali K Matta
Journal:  RSC Adv       Date:  2020-01-03       Impact factor: 4.036

7.  The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine.

Authors:  Michael T Truver; Gerd Jakobsson; Maria D Chermà; Madeleine J Swortwood; Henrik Gréen; Robert Kronstrand
Journal:  J Anal Toxicol       Date:  2022-02-14       Impact factor: 3.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.